Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I told everyone I'd be holding when the 4Q got here. I'm true to my word.
Looks like several others had the same idea, given the price movement.
Bout to soar!
Trading like a BEAST...going to soar over a dollar today EASILY.
She's going to zip over a dollar today, then it's off to the races.
I agree 100%. You should let the results from prior clinical studies help you in your decision to purchase Genta. It's overwhelmingly positive...approval is big dollars, folks.
Also, don't forget Genta leadership is looking for a partnership for Tesetaxel this year, the leading oral taxane in clinical development by miles (years).
Financing is in place and the Agenda results are right around the corner for world wide application. Anyone who's seen the results from the low to medium LDH levels knows this drug has a tremendous shot at approval coming up. Here are the last results. They are pretty amazing. We're talking a 15-20 dollar stock on confirmation of these data from the previous trial alone.
Extremely healthy...gonna be a massive breakout coming.
Gotta chase it now!
She's about to bounce.
You can look at my very first iHub post for my entry point. I was holding a few million shares at that level. I've done a pretty extensive amount of research here.
Contrary to popular belief...
...Genta is not a pinksheet stock. It's OTCBB.
If there is a pullback, it will be a dip after an initial pop in the morning, then it's off to the races.
Genta made a lot of money for a lot of folks a few short months ago, and with the real prize on the horizon, she's going to run hard for a while.
I wouldn't sell a share until I heard on the Agenda trial results.
New eyes turning in Genta's direction...
...old one's who are being reminded that their time is near.
You'll be lucky to catch this under a dollar in the morning.
This is setting up exactly like DNDN. That's not a pump; that's the reality of what can happen in just a few short months.
Thank you, sir. I plan on it...
...and you're right, your time has come. Lots on the horizon for Genta's faithful shareholders.
2 blockbuster drugs in late stage trials. Genasense in the treatment of melanoma...yessir...this stock can hit 15-20 dollars by the end of the year easily.
Blockbuster treatment on the way. Financing squared away.
If you sell Genta at this point, you're losing. It will move north and pull back, but let me assure you all of this: There is a ruling coming from the FDA on the Agenda Clinical Trial and my money is on approval. The evidence is too overwhelming using the biomarker of interest.
Genta obtains worldwide approval for Oblimersen (Genasense).
Exciting times!
I knew that .35 felt like the right entry point ;)
Hope you made a killin' smitter.
Looks like a party ova here!
Congrats, Genta longs!
MrBigz...
...It would be a huge help for me if you could take a look at the CNO chart. You've helped me out before when I needed some assistance, so I figured I'd go back to the well one more time. If you don't have time to look, that's ok too.
Thanks and best of luck this week.
-Holding
Has anyone looked at CNO? Tons of room to run up through earnings release in early November. Easy double. Not a micro penny stock, but tons of potential.
Seriously. Go look.
CNO is going to fly.
Has anyone researched Conseco (CNO)?
This stock is really ready to make a move, just throwing it out there for those who might be interested in reading up on fundamentals. Anything under 13 dollars is undervalued.
It's Friday...
...but it's definitely time to get into Genta if you want to get bottom level prices prior to Agenda results.
Hey, looky here. She's running.
They're certainly working more efficiently by reducing headcount and workspace needs. Everything this company has, past and present, will be riding on the Agenda results.
I think they'll be strong.
Financials have never and will never be good...
....for Genta until it receives approval for a drug other than Ganite. It's a research and development company who has never been profitable in over 20 years.
That role has been there for a year.
Well, learn to quote and reply to the right people to avoid confusion.
I was never talking about the SEC filing, sir.
You're welcome to call it whatever you want.
Looking back on the presentation made in February, Genta leadership was exploring more Tesetaxel opportunities. We all saw how far ahead Genta was with the RnD on Tesetaxel. You're talking about a cancer treatment, in pill form, that can be taken at home instead of going into the hospital and being hooked up to IV's with nurses and monitors...virtually eliminating all overhead from hospital care. Can you even start to put a price tag on that type of medication? I didn't think so.
You, bundleofshares, need to do more DD on this company. Take a look at the below slide presented by Genta leadership at the 2009 BIO CEO Investors Conference.
I fully expect to hear some news on Tesetaxel prior to any Agenda results. This will nudge the share price (or give it a serious boost) prior to Agenda results in Q4.
Now is the time to be loading up. You make your own call, I'll make mine.
Things will get moving north soon.
Can't be too sure, but...
...I feel the ask is about to tick up on this thing.
Keep your eyes peeled, we all know how quickly Genta can move.
Smitter, I'm being serious. I've been watching this for weeks now. It's about time.
Buy this stock now.
I didn't pull the trigger yet...
...but I'm getting dangerously close.
It's about that time to start getting some positive momentum. It's fallen 25% from its R/S date and seems to be maintaining these levels fairly well. Almost where I want to see it.
I think we're going to get some news on a Tesetaxel partnership soon. Keep your ear to the ground.
Agenda results aren't too far off and speculation on those results should start soon.
It's starting to look like a nice entry point, from my perspective.
To the gentlemen who asked about forecasted PPS with Tesetaxel or Genasense approval in the treatment of melanoma...huge.
Tesetaxel, though a ways off, is easily triple the value of Genasense in Melanoma. The production of that drug depends squarely on the approval of the next NDA on Melanoma treatment.
Approval of Genasense alone puts the pps somewhere in the 15-20 dollar range, no hesitation.
Tesetaxel somewhere close to 30. That's a big time drug and it's off a lot of people's radar in terms of potential.
Keep your ear to the ground.
-Holder
If you're expecting something exciting from Q2 earnings, you need to do more DD. Genta has never been profitable in 20 years.
It's not about being profitable for a research and development company. It's about getting a blockbuster to market.
Genasense is pretty close.
I'm not sure, it just feels right.
I'm about to take a large position here.
Going to be another great day...
...the close yesterday was all I needed to see. No one was willing to sell at 2.91 and those who were got met with eager buyers. Tremendous support here with tons of room to move north.
This security is very undervalued and is just getting started. Look at the volume over the past 2 trading days and the price range that trading took place in. It'll give you a warm and fuzzy feeling that it's ok to add here.
This might be the strongest base support CNO has ever had, putting in a very strong bottom.
Buy with confidence. She's going to soar.
Opportunity Cost
July 28 (Bloomberg) -- Shares of the following companies may have unusual moves in U.S. trading tomorrow. Stock symbols are in parentheses, and prices are as of 6 p.m. in New York.
Standard & Poor’s 500 Index futures expiring in September fell 0.2 percent to 973.7.
Conseco Inc. (CNO:US) jumped 21 percent to $2.29. The Carmel, Indiana-based life insurer said it had a second-quarter profit and that results complied with credit agreement covenants.
http://www.bloomberg.com/apps/news?pid=stocksonmove
BOOOOYA STRAIGHT TO $10!!
Agree...
...the news is not old as it relates to the drugs and what they do, but these articles have already been priced in to the security.
3 months old is old news when you're talking stock price. 3 day news is old news.
Yep, I feel like this is a great base price to buy in. This stock sees explosive moves north.